2024-513746-11-00CompletedPhase 3
Neovascular glaucoma prevention by intravitreal injections of anti-VEGF in patients treated by protontherapy in case of large choroid melanoma
Source: EU CTIS (euclinicaltrials.eu) · Last updated 19 Dec 2024
Brief summary (registry, in English)
Compare neovascular glaucoma rate 5 years after proton therapy, in patients large with choroid melanoma, between a group of patients treated preventively by intravitreal anti-VEGF versus a second group of patients receiving a false injection.
- Status (registry)
- Completed
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 56 (actual)
- First submitted
- 11 Sept 2024
- Start date
- 8 Jun 2017
- Lead sponsor
- Centre Hospitalier Universitaire De Nice
- Diseases
- Melanoma
- EU CT number
- 2024-513746-11-00
- EudraCT number
- 2016-003329-40
What you commit to
- Study type: Interventional · Phase 3
- Participants enrolled: 56
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Who cannot take part
Copied verbatim from EU CTIS (euclinicaltrials.eu) and grouped by topic. Only the trial team decides who can take part.
Other illness
- Known hypersensitivity to aflibercept (anti-VEGF selected)
Other
- Iris melanoma
- Melanoma immediately metastatic
- Pregnant or breastfeeding women
Who the study is looking for
- Age ≥ 18 years
- Choroid melanoma more than 7 mm thick and / or over basal diameter of 15mm treated by proton therapy
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (3)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Centre Rétine Gallien | Bordeaux | France | Completed |
| Centre Hospitalier Universitaire de Nice | Nice | France | Completed |
| Quinze-Vingts National Ophthalmology Hospital | Paris | France | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.